Creating value in the lives of the people we serve, now and into the future UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge UCB share price More in UCB Shares Consensus by Visible Alpha Financial & Extra Financial performance Equity Story Download Center Corporate Governance Shareholders Financial Guidance The figures of the guidance 2025 as mentioned below were calculated on the same basis as the actual figures for 2024 and based on current rules and regulations. 2025 Revenue at least € 7.6bnUpdated as per 5 December 2025Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, with BIMZELX® outperforming expectations on the back of strong patient demand and a more favorable U.S. payer mix 2025 adj. EBITDA at least 31%Updated as per 5 December 2025Continued gross margin improvement, operating leverage improvement, continued growth of marketing and sales expenses driven by top-line growth and maintained investment in R&D 2025 Core EPS at least € 7.25based on an average of 190 million shares outstanding and tax rate of 20% Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.comDiyana Mishu, Investor Relations ManagerTel: +32 2 599 7446E-mail: Diyana.Mishu@ucb.com Book a virtual meeting Send us feedback UCB IR App
